These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 11691826

  • 21. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
    Forster K, Obermeier A, Mitina O, Simon N, Warmuth M, Krause G, Hallek M.
    Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148.
    Dan S, Naito M, Tsuruo T.
    Cell Death Differ; 1998 Aug; 5(8):710-5. PubMed ID: 10200527
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
    Zhelev Z, Bakalova R, Ohba H, Ewis A, Ishikawa M, Shinohara Y, Baba Y.
    FEBS Lett; 2004 Jul 16; 570(1-3):195-204. PubMed ID: 15251464
    [Abstract] [Full Text] [Related]

  • 29. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
    Czechowska A, Poplawski T, Drzewoski J, Blasiak J.
    Chem Biol Interact; 2005 Apr 15; 152(2-3):139-50. PubMed ID: 15840387
    [Abstract] [Full Text] [Related]

  • 30. Roots of imatinib resistance: a question of self-renewal?
    Burchert A.
    Drug Resist Updat; 2007 Apr 15; 10(4-5):152-61. PubMed ID: 17683977
    [Abstract] [Full Text] [Related]

  • 31. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
    Pytel D, Wysocki T, Majsterek I.
    Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep 15; 144(1):85-92. PubMed ID: 16904383
    [Abstract] [Full Text] [Related]

  • 32. [Cyclin D2 expression in chronic myelogenous leukemia].
    Song JM, Xu D, Fan EJ, Xu SR, Li D, Zhao CH.
    Zhonghua Xue Ye Xue Za Zhi; 2004 Feb 15; 25(2):103-5. PubMed ID: 14990053
    [Abstract] [Full Text] [Related]

  • 33. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N.
    Rinsho Byori; 2004 Feb 15; 52(2):136-44. PubMed ID: 15027317
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
    Iolascon A, Della Ragione F, Giordani L, Serra A, Saglio G, Faienza MF.
    Haematologica; 1998 Sep 15; 83(9):771-7. PubMed ID: 9825572
    [Abstract] [Full Text] [Related]

  • 37. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
    Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE, Toyama K.
    Exp Hematol; 1995 Oct 15; 23(11):1153-9. PubMed ID: 7556524
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.